In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers have identified a protein called non-structural protein 15 (nsp15) that plays a key role in helping SARS-CoV-2 hide from the body’s defenses by suppressing the production of viral double-stranded (dsRNA), leading to increased viral replication while limiting the body’s immune response.

By creating a cohesive AI-enabled and physics-based molecular modeling and drug discovery pipeline built around film industry animation software, researchers at the Wyss Institute at Harvard University identified the orally available, FDA-approved drug bemcentinib, as a potential antiviral agent. They then used this chemical compound as a launch pad for developing a more specific and effective antiviral drug with efficacy against a broad range of coronaviruses, which has great potential for fighting future respiratory pandemics. 

The use of complementary and alternative medicine (CAM) has remained fairly steady across Europe over the past decade. However, significant disparities exist between countries.

Contrary to expectations, the Covid pandemic did not cause a spike in the overall use of CAM in Europe: the growth was modest, from 27% in 2014 to 28% in 2023. These University of Helsinki findings are reported in an article published in the Journal of Public Health.

UK-ROX, the largest ever clinical trial of oxygen use in UK intensive care units (ICUs), has shown that reducing supplementary oxygen does not deliver any clear and obvious health benefits or harm a patient's chances of survival. Each year, around 184,000 patients are admitted to ICUs, but there is insufficient evidence to guide the use of oxygen, with the possibility that administering too much - or too little - may not deliver the intended benefits and actually end up causing patients additional harm. UK-ROX, led by the University of Plymouth and the Intensive Care National Audit & Research Centre, set out to fill that evidence gap and the results have been presented to delegates at the Critical Care Reviews Meeting 2025 in Belfast this morning, and published in the JAMA journal.

About The Study: In this cross-sectional study using data from the Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research database, alcohol-associated liver disease mortality increased significantly across demographic groups, with particularly concerning trends among women, younger adults, and American Indian and Alaska Native populations. These findings highlight the urgent need for targeted public health interventions and enhanced surveillance, especially given the sustained impact of COVID-19 pandemic–related changes in alcohol consumption patterns. 

The Covid-19 pandemic, Russia’s war on Ukraine, geopolitical tensions, climate change and other events highlight our growing exposure to complex, interconnected, and intertwining risks. In view of this development, the focus of risk research has shifted towards the comprehensive analysis of interconnected and mutually interactive risk sources and crises. In a review article published in the  International Journal of Disaster Risk Science Huan Liu (Kyoto University) and Ortwin Renn (Research Institute for Sustainability, RIFS) offer an overview of the current state of research on polycrises and systemic risks.

New research indicates that children infected with COVID-19 may face increased cardiovascular disease risks indicated by blood plasma metabolic changes.

A new study reveals that the SARS-CoV-2 nucleocapsid protein can spread from infected to uninfected cells, triggering an immune response that mistakenly targets healthy cells. The research identifies how this viral protein binds to cell surfaces and shows that enoxaparin, a common anticoagulant, can block this harmful interaction, pointing to a potential avenue for treatment. These findings shed light on the mechanisms behind severe COVID-19 complications and immune-driven tissue damage.

People with COVID-like symptoms returned to optimal physical well-being an average of three months after infection, but took up to nine months to return to top mental well-being.  One year after infection about 20% of study participants continued to experience overall suboptimal health-related quality of life.

Penn Vet and Penn Medicine researchers have modified mRNA vaccines to include the cytokine IL-12 and improve T cell responses which could improve the body’s ability to fight infections.

A new AI tool to predict the spread of infectious disease outperforms existing state-of-the-art forecasting methods.

The tool, created with federal support by researchers at Johns Hopkins and Duke universities, could revolutionize how public health officials predict, track and manage outbreaks of infectious diseases including flu and COVID-19.